QIAGEN Reports Q3 2026 Results, Sales Rise 3% to $548 Million
QIAGEN said third-quarter sales and adjusted diluted EPS were ahead of its outlook, in line with preliminary results. Sales rose 3% year over year to $548 million.
Story updates
09:07:51 PM UTC
SquawkNews
QIAGEN N.V. reported Q3 2026 sales of $548M, up 3% from Q3 2025 and above its outlook for about 1-2% CER growth. Adjusted diluted EPS rose to $0.65 from $0.61, exceeding the outlook for at least $0.62 CER.Material DetailsContext by AI AnalystThis is a full quarterly results report that confirms the…
09:09:04 PM UTC
SquawkNews
Q3 2026 results: Net sales of $548 million rise 3% and also 3% at constant exchange rates (CER) Adju
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced full results for the third quarter of 2026, with net sales and adjusted diluted earnings per share (EPS) ahead of the outlook.In line with preliminary results, Q3 2026 sales rose 3% to $548 million compared with Q3 2025, also in…